Chronic lymphoproliferative diseases and cardiovascular risk (a literature review)
DOI:
https://doi.org/10.14739/2310-1210.2022.5.266062Keywords:
cardiovascular events, cardiotoxicity, polychemotherapy, diagnostics, prognostic factorsAbstract
Heart dysfunction that occurred after using of anticancer drugs and monoclonal antibodies may be a limit factor in treatment of chronic lymphoproliferative diseases (CLPD). Cancer therapy-related cardiovascular toxicity include hypotension, hypertension, arrhythmias, conduction disturbances, pericarditis, thromboembolic events, heart failure, death. The risk of cardiotoxicity may be increased by some factors that include drug exposure, age, history of heart diseases, arterial hypertension, drug combination, previous radiotherapy or chemotherapy.
The aim of the work is to assess the impact of anticancer treatment on the occurrence of cardiovascular events in patients with CLPD according to the world scientific literature data.
It is important to detect the cardiovascular toxicity before the development of clinical manifestations of damage to the myocardium and blood vessels. The role of markers in identifying the risk group of adverse cardiovascular events remains unclear. Early diagnostics and determination of prognostic factors of cardiovascular toxicity, which develop after anticancer therapy of CLPD, are important and not solved problems.
Conclusions. The prognosis for the development of cardiovascular events after antitumor treatment of CLPD remains unfavorable. Clinical monitoring, imaging methods, determination of the biomarker levels (natriuretic peptides, troponins) for cardiotoxicity risk stratification are recommended during antitumor treatment to identify early signs and risk of cardiotoxicity. The use of the latest biomarkers and their combinations may be a way to improve the assessment of the cardiotoxicity risk in CLPD. To date, there is no sufficient evidence on the feasibility of routine determining these biomarkers, which indicates the need to plan new studies.
References
Novak, V. L., Masliak, Z. V., Klymenko, S. V., Voitsitskyi, Yu. V., Bereketa, Ya. D., Prymak, S. V., & Hutor, T. H. (2017). Pokaznyky diialnosti hematolohichnoi sluzhby Ukrainy v 2016 rotsi [Performance indicators of the hematology service of Ukraine in 2016]. Lviv, 2017, 44. [in Ukrainian].
Ukrainian cancer registry statistics. (2019). Rak v Ukraini, 2017-2018. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby [Cancer in Ukraine, 2017-2018. Occupation, death, demonstration of oncological service]. Bulletin of National Cancer Registry of Ukraine, 20. [in Ukrainian].
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660
Ewer, M. S., & Ewer, S. M. (2015). Cardiotoxicity of anticancer treatments. Nature reviews. Cardiology, 12(9), 547-558. https://doi.org/10.1038/nrcardio.2015.65
Kryachok, I. A., & Tytorenko, I. B. (2014). Kardiotoksychnist pry provedenni khimioterapevtychnoho likuvannia u patsiientiv pokhyloho viku iz nekhodzhkinskymy limfomamy [Chemotherapy-related cardiotoxicity in elderly patients with non-Hodgkin lymphoma]. Klinicheskaya onkologiya, (1), 69-73. [in Ukrainian].
Tseluiko, V. Y., & Radchenko, O. V. (2018). Serdechno-sosudistye zabolevaniya u onkologicheskikh bolnykh. Liky Ukrainy, (3), 7-20. [in Russian].
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., Moslehi, J., … ESC Scientific Document Group (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal, ehac244. Advance online publication. https://doi.org/10.1093/eurheartj/ehac244
Gilchrist, S. C., Barac, A., Ades, P. A., Alfano, C. M., Franklin, B. A., Jones, L. W., La Gerche, A., Ligibel, J. A., Lopez, G., Madan, K., Oeffinger, K. C., Salamone, J., Scott, J. M., Squires, R. W., Thomas, R. J., Treat-Jacobson, D. J., Wright, J. S., & American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease (2019). Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation, 139(21), e997-e1012. https://doi.org/10.1161/CIR.0000000000000679
Vatutin, N. T., Sklyanaya, E. V., Shevelek, A. N., Smirnova, A. S., El'-Khatib, M. A., Gritsenko, Yu. P., Kolesnikov, V. S., & Taratorina, A. A. (2017). Preparaty, vyzyvayushchie ili ukhudshayushchie techenie serdechnoi nedostatochnosti. Obzor rekomendatsii Amerikanskoi assotsiatsii serdtsa [Drugs that cause or worsen heart failure. Review of American Heart Association Guidelines]. Praktychna anhiolohiia, (1), 52-56. [in Russian].
Kevane, B., Crowley, M. P., Bolster, M., & Gilligan, O. (2014). Myeloma relapse involving the heart and presenting as acute cardiac failure. Journal of clinical oncology, 32(18), e67-e68. https://doi.org/10.1200/JCO.2012.47.6713
Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Wimperis, J., Culligan, D., Popova, B., Smith, P., McMillan, A., Brownell, A., Kruger, A., Lister, A., Hoskin, P., O'Doherty, M., & Barrington, S. (2015). Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. The New England journal of medicine, 372(17), 1598-1607. https://doi.org/10.1056/NEJMoa1408648
Schaapveld, M., Aleman, B. M., van Eggermond, A. M., Janus, C. P., Krol, A. D., van der Maazen, R. W., Roesink, J., Raemaekers, J. M., de Boer, J. P., Zijlstra, J. M., van Imhoff, G. W., Petersen, E. J., Poortmans, P. M., Beijert, M., Lybeert, M. L., Mulder, I., Visser, O., Louwman, M. W., Krul, I. M., Lugtenburg, P. J., … van Leeuwen, F. E. (2015). Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. The New England journal of medicine, 373(26), 2499-2511. https://doi.org/10.1056/NEJMoa1505949
De Luca, V., Gallio, E., Bartoncini, S., Giglioli, F. R., Sardo, A., Cavallin, C., Iorio, G. C., Orlandi, E., Parise, R., Palladino, C., Buonavita, A., Fiandra, C., Levis, M., & Ricardi, U. (2021). Adoption of Expansion Margins to Reduce the Dose Received by the Coronary Arteries and the Risk of Cardiovascular Events in Lymphoma Patients. Practical radiation oncology, 11(1), 66-73. https://doi.org/10.1016/j.prro.2020.06.005
Gevaert, S. A., Halvorsen, S., Sinnaeve, P. R., Sambola, A., Gulati, G., Lancellotti, P., Van Der Meer, P., Lyon, A. R., Farmakis, D., Lee, G., Boriani, G., Wechalekar, A., Okines, A., & Asteggiano, R. (2021). Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. European heart journal. Acute cardiovascular care, 10(8), 947-959. https://doi.org/10.1093/ehjacc/zuab056
van Nimwegen, F. A., Schaapveld, M., Janus, C. P., Krol, A. D., Petersen, E. J., Raemaekers, J. M., Kok, W. E., Aleman, B. M., & van Leeuwen, F. E. (2015). Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA internal medicine, 175(6), 1007-1017. https://doi.org/10.1001/jamainternmed.2015.1180
van Nimwegen, F. A., Schaapveld, M., Cutter, D. J., Janus, C. P., Krol, A. D., Hauptmann, M., Kooijman, K., Roesink, J., van der Maazen, R., Darby, S. C., Aleman, B. M., & van Leeuwen, F. E. (2016). Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. Journal of clinical oncology, 34(3), 235-243. https://doi.org/10.1200/JCO.2015.63.4444
Akazawa H. (2017). [Cardiotoxicity of Cancer Chemotherapy - Mechanisms and Therapeutic Approach]. Cancer & chemotherapy, 44(13), 2058-2063.
Rokyta, O. I., & Rudenko, Yu. V. (2017). Likuvannia onkolohichnykh zakhvoriuvan i sertsevo-sudynna toksychnist. Tochka zoru Yevropeiskoho tovarystva kardiolohiv. Chastyna I [Treatment of oncological diseases and cardiovascular toxicity. Viewpoint of the European Society of Cardiology. Part 1]. Sertse i sudyny, (2), 11-19. [in Ukrainian].
Bahia, L., de Aguiar, L. G., Villela, N. R., Bottino, D., & Bouskela, E. (2006). O endotélio na síndrome metabólica [The endothelium in the metabolic syndrome]. Arquivos brasileiros de endocrinologia e metabologia, 50(2), 291-303. https://doi.org/10.1590/s0004-27302006000200015
Suter, T. M., & Ewer, M. S. (2013). Cancer drugs and the heart: importance and management. European heart journal, 34(15), 1102-1111. https://doi.org/10.1093/eurheartj/ehs181
Skrypnyk, I. M., Maslova, H. S., & Lymanets, T. V. (2016). Ishemichna khvoroba sertsia yak faktor ryzyku antratsyklinindukovanoi kardiotoksychnosti [Ischemic heart disease as a risk factor for anthracycline-induced cardiotoxicity]. Vrachebnoe delo, (5-6), 47-52. [in Ukrainian].
Gulati, A., Jabbour, A., Ismail, T. F., Guha, K., Khwaja, J., Raza, S., Morarji, K., Brown, T. D., Ismail, N. A., Dweck, M. R., Di Pietro, E., Roughton, M., Wage, R., Daryani, Y., O'Hanlon, R., Sheppard, M. N., Alpendurada, F., Lyon, A. R., Cook, S. A., Cowie, M. R., … Prasad, S. K. (2013). Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA, 309(9), 896-908. https://doi.org/10.1001/jama.2013.1363
Khouri, M. G., Douglas, P. S., Mackey, J. R., Martin, M., Scott, J. M., Scherrer-Crosbie, M., & Jones, L. W. (2012). Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation, 126(23), 2749-2763. https://doi.org/10.1161/CIRCULATIONAHA.112.100560
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., Jerusalem, G., … Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European heart journal. Cardiovascular Imaging, 15(10), 1063-1093. https://doi.org/10.1093/ehjci/jeu192
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., Suter, T. M., & ESC Scientific Document Group (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European heart journal, 37(36), 2768-2801. https://doi.org/10.1093/eurheartj/ehw211
Lyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., Tocchetti, C. G., Moslehi, J. J., Groarke, J. D., Bergler-Klein, J., Khoo, V., Tan, L. L., Anker, M. S., von Haehling, S., Maack, C., Pudil, R., Barac, A., Thavendiranathan, P., Ky, B., Neilan, T. G., … Lenihan, D. (2020). Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European journal of heart failure, 22(11), 1945-1960. https://doi.org/10.1002/ejhf.1920
Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., Fiorentini, C., & Cipolla, C. M. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation, 131(22), 1981-1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777
Wang, L., Tan, T. C., Halpern, E. F., Neilan, T. G., Francis, S. A., Picard, M. H., Fei, H., Hochberg, E. P., Abramson, J. S., Weyman, A. E., Kuter, I., & Scherrer-Crosbie, M. (2015). Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. The American journal of cardiology, 116(3), 442-446. https://doi.org/10.1016/j.amjcard.2015.04.064
Armenian, S. H., Hudson, M. M., Mulder, R. L., Chen, M. H., Constine, L. S., Dwyer, M., Nathan, P. C., Tissing, W. J., Shankar, S., Sieswerda, E., Skinner, R., Steinberger, J., van Dalen, E. C., van der Pal, H., Wallace, W. H., Levitt, G., Kremer, L. C., & International Late Effects of Childhood Cancer Guideline Harmonization Group (2015). Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet. Oncology, 16(3), e123-e136. https://doi.org/10.1016/S1470-2045(14)70409-7
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., Suter, T. M., Zamorano, J. L., Aboyans, V., Achenbach, S., Agewall, S., … Document Reviewers (2017). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European journal of heart failure, 19(1), 9-42. https://doi.org/10.1002/ejhf.654
Askolskyi, A. V., Sivak, L. A., Zharinov, O. I., Antomonov, M. Y., & Shevchuk, L. A. (2017). Profilaktyka rannoi antratsyklin-indukovanoi kardiotoksychnosti polikhimioterapii u khvorykh na rak hrudnoi zalozy [Prevention of early anthracycline-induced cardiotoxicity in patients with breast cancer]. Klinicheskaya onkologiya, (1), 45-50. [in Ukrainian].
Drafts, B. C., Twomley, K. M., D'Agostino, R., Jr, Lawrence, J., Avis, N., Ellis, L. R., Thohan, V., Jordan, J., Melin, S. A., Torti, F. M., Little, W. C., Hamilton, C. A., & Hundley, W. G. (2013). Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC. Cardiovascular imaging, 6(8), 877-885. https://doi.org/10.1016/j.jcmg.2012.11.017
Gribben, J. G., Bosch, F., Cymbalista, F., Geisler, C. H., Ghia, P., Hillmen, P., Moreno, C., & Stilgenbauer, S. (2018). Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. British journal of haematology, 180(5), 666-679. https://doi.org/10.1111/bjh.15080
Dickerson, T., Wiczer, T., Waller, A., Philippon, J., Porter, K., Haddad, D., Guha, A., Rogers, K. A., Bhat, S., Byrd, J. C., Woyach, J. A., Awan, F., & Addison, D. (2019). Hypertension and incident cardiovascular events following ibrutinib initiation. Blood, 134(22), 1919-1928. https://doi.org/10.1182/blood.2019000840
Salem, J. E., Manouchehri, A., Bretagne, M., Lebrun-Vignes, B., Groarke, J. D., Johnson, D. B., Yang, T., Reddy, N. M., Funck-Brentano, C., Brown, J. R., Roden, D. M., & Moslehi, J. J. (2019). Cardiovascular Toxicities Associated With Ibrutinib. Journal of the American College of Cardiology, 74(13), 1667-1678. https://doi.org/10.1016/j.jacc.2019.07.056
Byrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A., Furman, R. R., O'Brien, S., Yenerel, M. N., Illés, A., Kay, N., Garcia-Marco, J. A., Mato, A., Pinilla-Ibarz, J., Seymour, J. F., Lepretre, S., Stilgenbauer, S., Robak, T., Rothbaum, W., Izumi, R., Hamdy, A., … Jurczak, W. (2021). Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of clinical oncology, 39(31), 3441-3452. https://doi.org/10.1200/JCO.21.01210
Brown, J. R., Byrd, J. C., Ghia, P., Sharman, J. P., Hillmen, P., Stephens, D. M., Sun, C., Jurczak, W., Pagel, J. M., Ferrajoli, A., Patel, P., Tao, L., Kuptsova-Clarkson, N., Moslehi, J., & Furman, R. R. (2022). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica, 107(6), 1335-1346. https://doi.org/10.3324/haematol.2021.278901
Svennberg, E., Tjong, F., Goette, A., Akoum, N., Di Biase, L., Bordachar, P., Boriani, G., Burri, H., Conte, G., Deharo, J. C., Deneke, T., Drossart, I., Duncker, D., Han, J. K., Heidbuchel, H., Jais, P., de Oliviera Figueiredo, M. J., Linz, D., Lip, G., Malaczynska-Rajpold, K., … Sinner, M. (2022). How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace, 24(6), 979-1005. https://doi.org/10.1093/europace/euac038
Abdel-Qadir, H., Sabrie, N., Leong, D., Pang, A., Austin, P. C., Prica, A., Nanthakumar, K., Calvillo-Argüelles, O., Lee, D. S., & Thavendiranathan, P. (2021). Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. Journal of clinical oncology, 39(31), 3453-3462. https://doi.org/10.1200/JCO.21.00693
Waxman, A. J., Clasen, S., Hwang, W. T., Garfall, A., Vogl, D. T., Carver, J., O'Quinn, R., Cohen, A. D., Stadtmauer, E. A., Ky, B., & Weiss, B. M. (2018). Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA oncology, 4(3), e174519. https://doi.org/10.1001/jamaoncol.2017.4519
Siegel, D., Martin, T., Nooka, A., Harvey, R. D., Vij, R., Niesvizky, R., Badros, A. Z., Jagannath, S., McCulloch, L., Rajangam, K., & Lonial, S. (2013). Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica, 98(11), 1753-1761. https://doi.org/10.3324/haematol.2013.089334
Cornell, R. F., Ky, B., Weiss, B. M., Dahm, C. N., Gupta, D. K., Du, L., Carver, J. R., Cohen, A. D., Engelhardt, B. G., Garfall, A. L., Goodman, S. A., Harrell, S. L., Kassim, A. A., Jadhav, T., Jagasia, M., Moslehi, J., O'Quinn, R., Savona, M. R., Slosky, D., Smith, A., … Lenihan, D. (2019). Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. Journal of clinical oncology, 37(22), 1946-1955. https://doi.org/10.1200/JCO.19.00231
Fakhri, B., Fiala, M. A., Shah, N., Vij, R., & Wildes, T. M. (2020). Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database. Cancer, 126(4), 808-813. https://doi.org/10.1002/cncr.32601
Mancuso, S., Carlisi, M., Sarocchi, M., Napolitano, M., & Siragusa, S. (2018). Cardio-oncology in multiple myeloma: is it time for a specific focus?. Leukemia & lymphoma, 59(7), 1764-1766. https://doi.org/10.1080/10428194.2017.1393674
Danhof, S., Schreder, M., Rasche, L., Strifler, S., Einsele, H., & Knop, S. (2016). 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors. European journal of haematology, 97(1), 25-32. https://doi.org/10.1111/ejh.12677
Gavazzoni, M., Lombardi, C. M., Vizzardi, E., Gorga, E., Sciatti, E., Rossi, L., Belotti, A., Rossi, G., Metra, M., & Raddino, R. (2018). Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. European journal of pharmacology, 838, 85-90. https://doi.org/10.1016/j.ejphar.2018.09.014
Fradley, M. G., Groarke, J. D., Laubach, J., Alsina, M., Lenihan, D. J., Cornell, R. F., Maglio, M., Shain, K. H., Richardson, P. G., & Moslehi, J. (2018). Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. British journal of haematology, 180(2), 271-275. https://doi.org/10.1111/bjh.14970
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., … ASPIRE Investigators (2015). Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. The New England journal of medicine, 372(2), 142-152. https://doi.org/10.1056/NEJMoa1411321
Willis, M. S., & Patterson, C. (2013). Proteotoxicity and cardiac dysfunction--Alzheimer's disease of the heart?. The New England journal of medicine, 368(5), 455-464. https://doi.org/10.1056/NEJMra1106180
Castel, M., Despas, F., Modesto, A., Gales, C., Honton, B., Galinier, M., Senard, J. M., & Pathak, A. (2013). Effets indésirables cardiaques des chimiothérapies [Cardiotoxicity of chemotherapies]. Presse medicale, 42(1), 26-39. https://doi.org/10.1016/j.lpm.2012.04.014
Nesen, A. O. (2014). Khronichni neinfektsiini zakhvoriuvannia: aktsent na komorbidnist i pidvyshchenyi kardiovasuliarnyi ryzyk [Chronic noncommunicable diseases: emphasis on comorbidity and increased cardiovascular risk]. Ukrainskyi terapevtychnyi zhurnal, 2, 26-32. [in Ukrainian].
Lancellotti, P., Suter, T. M., López-Fernández, T., Galderisi, M., Lyon, A. R., Van der Meer, P., Cohen Solal, A., Zamorano, J. L., Jerusalem, G., Moonen, M., Aboyans, V., Bax, J. J., & Asteggiano, R. (2019). Cardio-Oncology Services: rationale, organization, and implementation. European heart journal, 40(22), 1756-1763. https://doi.org/10.1093/eurheartj/ehy453
Jaworski, C., Mariani, J. A., Wheeler, G., & Kaye, D. M. (2013). Cardiac complications of thoracic irradiation. Journal of the American College of Cardiology, 61(23), 2319-2328. https://doi.org/10.1016/j.jacc.2013.01.090
Vydyborets, S. V., Hartovska, I. R., Borysenko, Ye. O., & Maiko, O. V. Markery endohennoi intoksykatsii ta infuziino-transfuziina terapiia khvorykh na hostri leikozy v protsesi intensyvnoi khimioterapii [Markers of endogenous intoxication and infusion-transfusion therapy of patients with hostile leukemia during intensive chemotherapy]. Semeinaya meditsina, (6), 111-114. [in Ukrainian].
Visseren, F., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J. M., Capodanno, D., Cosyns, B., Crawford, C., Davos, C. H., Desormais, I., Di Angelantonio, E., Franco, O. H., Halvorsen, S., Hobbs, F., Hollander, M., Jankowska, E. A., … ESC Scientific Document Group (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European heart journal, 42(34), 3227-3337. https://doi.org/10.1093/eurheartj/ehab484
Chow, E. J., Chen, Y., Kremer, L. C., Breslow, N. E., Hudson, M. M., Armstrong, G. T., Border, W. L., Feijen, E. A., Green, D. M., Meacham, L. R., Meeske, K. A., Mulrooney, D. A., Ness, K. K., Oeffinger, K. C., Sklar, C. A., Stovall, M., van der Pal, H. J., Weathers, R. E., Robison, L. L., & Yasui, Y. (2015). Individual prediction of heart failure among childhood cancer survivors. Journal of clinical oncology, 33(5), 394-402. https://doi.org/10.1200/JCO.2014.56.1373
Szmit, S., Jurczak, W., Zaucha, J. M., Drozd-Sokołowska, J., Spychałowicz, W., Joks, M., Długosz-Danecka, M., & Torbicki, A. (2014). Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. Journal of the American Society of Hypertension : JASH, 8(11), 791-799. https://doi.org/10.1016/j.jash.2014.08.009
Armstrong, G. T., Oeffinger, K. C., Chen, Y., Kawashima, T., Yasui, Y., Leisenring, W., Stovall, M., Chow, E. J., Sklar, C. A., Mulrooney, D. A., Mertens, A. C., Border, W., Durand, J. B., Robison, L. L., & Meacham, L. R. (2013). Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. Journal of clinical oncology, 31(29), 3673-3680. https://doi.org/10.1200/JCO.2013.49.3205
Lancellotti, P., Nkomo, V. T., Badano, L. P., Bergler-Klein, J., Bogaert, J., Davin, L., Cosyns, B., Coucke, P., Dulgheru, R., Edvardsen, T., Gaemperli, O., Galderisi, M., Griffin, B., Heidenreich, P. A., Nieman, K., Plana, J. C., Port, S. C., Scherrer-Crosbie, M., Schwartz, R. G., Sebag, I. A., … Society of Cardiovascular Computed Tomography (2013). Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. European heart journal. Cardiovascular Imaging, 14(8), 721-740. https://doi.org/10.1093/ehjci/jet123
Lang, R. M., Badano, L. P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., Flachskampf, F. A., Foster, E., Goldstein, S. A., Kuznetsova, T., Lancellotti, P., Muraru, D., Picard, M. H., Rietzschel, E. R., Rudski, L., Spencer, K. T., Tsang, W., & Voigt, J. U. (2015). Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 28(1), 1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003
Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., Zamorano, J. L., … ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2020). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of oncology, 31(2), 171-190. https://doi.org/10.1016/j.annonc.2019.10.023
Čelutkienė, J., Pudil, R., López-Fernández, T., Grapsa, J., Nihoyannopoulos, P., Bergler-Klein, J., Cohen-Solal, A., Farmakis, D., Tocchetti, C. G., von Haehling, S., Barberis, V., Flachskampf, F. A., Čeponienė, I., Haegler-Laube, E., Suter, T., Lapinskas, T., Prasad, S., de Boer, R. A., Wechalekar, K., Anker, M. S., … Lyon, A. R. (2020). Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). European journal of heart failure, 22(9), 1504-1524. https://doi.org/10.1002/ejhf.1957
Hoffmann, R., Barletta, G., von Bardeleben, S., Vanoverschelde, J. L., Kasprzak, J., Greis, C., & Becher, H. (2014). Analysis of left ventricular volumes and function: a multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhanced and contrast-enhanced two-dimensional and three-dimensional echocardiography. Journal of the American Society of Echocardiography, 27(3), 292-301. https://doi.org/10.1016/j.echo.2013.12.005
van Kalsbeek, R. J., Mulder, R. L., Skinner, R., & Kremer, L. (2021). The Concept of Cancer Survivorship and Models for Long-Term Follow-Up. Frontiers of hormone research, 54, 1-15. https://doi.org/10.1159/000514693
Thavendiranathan, P., Negishi, T., Coté, M. A., Penicka, M., Massey, R., Cho, G. Y., Hristova, K., Vinereanu, D., Popescu, B. A., Izumo, M., Negishi, K., Marwick, T. H., & SUCCOUR Investigators (2018). Single Versus Standard Multiview Assessment of Global Longitudinal Strain for the Diagnosis of Cardiotoxicity During Cancer Therapy. JACC. Cardiovascular imaging, 11(8), 1109-1118. https://doi.org/10.1016/j.jcmg.2018.03.003
Oikonomou, E. K., Kokkinidis, D. G., Kampaktsis, P. N., Amir, E. A., Marwick, T. H., Gupta, D., & Thavendiranathan, P. (2019). Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis. JAMA cardiology, 4(10), 1007-1018. https://doi.org/10.1001/jamacardio.2019.2952
Cheng, S., Larson, M. G., McCabe, E. L., Osypiuk, E., Lehman, B. T., Stanchev, P., Aragam, J., Benjamin, E. J., Solomon, S. D., & Vasan, R. S. (2013). Reproducibility of speckle-tracking-based strain measures of left ventricular function in a community-based study. Journal of the American Society of Echocardiography, 26(11), 1258-1266.e2. https://doi.org/10.1016/j.echo.2013.07.002
Thavendiranathan, P., Poulin, F., Lim, K. D., Plana, J. C., Woo, A., & Marwick, T. H. (2014). Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. Journal of the American College of Cardiology, 63(25 Pt A), 2751-2768. https://doi.org/10.1016/j.jacc.2014.01.073
Tsai, H. R., Gjesdal, O., Wethal, T., Haugaa, K. H., Fosså, A., Fosså, S. D., & Edvardsen, T. (2011). Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. The American journal of cardiology, 107(3), 472-477. https://doi.org/10.1016/j.amjcard.2010.09.048
Mawad, W., & Friedberg, M. K. (2017). The continuing challenge of evaluating diastolic function by echocardiography in children: developing concepts and newer modalities. Current opinion in cardiology, 32(1), 93-100. https://doi.org/10.1097/HCO.0000000000000346
Voigt, J. U., Pedrizzetti, G., Lysyansky, P., Marwick, T. H., Houle, H., Baumann, R., Pedri, S., Ito, Y., Abe, Y., Metz, S., Song, J. H., Hamilton, J., Sengupta, P. P., Kolias, T. J., d'Hooge, J., Aurigemma, G. P., Thomas, J. D., & Badano, L. P. (2015). Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. European heart journal. Cardiovascular Imaging, 16(1), 1-11. https://doi.org/10.1093/ehjci/jeu184
Herrmann, J., Lenihan, D., Armenian, S., Barac, A., Blaes, A., Cardinale, D., Carver, J., Dent, S., Ky, B., Lyon, A. R., López-Fernández, T., Fradley, M. G., Ganatra, S., Curigliano, G., Mitchell, J. D., Minotti, G., Lang, N. N., Liu, J. E., Neilan, T. G., Nohria, A., … Valent, P. (2022). Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European heart journal, 43(4), 280-299. https://doi.org/10.1093/eurheartj/ehab674
Thavendiranathan, P., Grant, A. D., Negishi, T., Plana, J. C., Popović, Z. B., & Marwick, T. H. (2013). Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. Journal of the American College of Cardiology, 61(1), 77-84. https://doi.org/10.1016/j.jacc.2012.09.035
Houbois, C. P., Nolan, M., Somerset, E., Shalmon, T., Esmaeilzadeh, M., Lamacie, M. M., Amir, E., Brezden-Masley, C., Koch, C. A., Thevakumaran, Y., Yan, A. T., Marwick, T. H., Wintersperger, B. J., & Thavendiranathan, P. (2021). Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography. JACC. Cardiovascular imaging, 14(5), 962-974. https://doi.org/10.1016/j.jcmg.2020.09.039
Armstrong, G. T., Plana, J. C., Zhang, N., Srivastava, D., Green, D. M., Ness, K. K., Daniel Donovan, F., Metzger, M. L., Arevalo, A., Durand, J. B., Joshi, V., Hudson, M. M., Robison, L. L., & Flamm, S. D. (2012). Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. Journal of clinical oncology, 30(23), 2876-2884. https://doi.org/10.1200/JCO.2011.40.3584
Phillips, W. J., Johnson, C., Law, A., Turek, M., Small, A. R., Dent, S., Ruddy, T. D., Beanlands, R. S., Chow, B., & Small, G. R. (2019). Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events. International journal of cardiology, 289, 138-143. https://doi.org/10.1016/j.ijcard.2019.01.056
Porta-Sánchez, A., Gilbert, C., Spears, D., Amir, E., Chan, J., Nanthakumar, K., & Thavendiranathan, P. (2017). Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. Journal of the American Heart Association, 6(12), e007724. https://doi.org/10.1161/JAHA.117.007724
Praga, C., Beretta, G., Vigo, P. L., Lenaz, G. R., Pollini, C., Bonadonna, G., Canetta, R., Castellani, R., Villa, E., Gallagher, C. G., von Melchner, H., Hayat, M., Ribaud, P., De Wasch, G., Mattsson, W., Heinz, R., Waldner, R., Kolaric, K., Buehner, R., Ten Bokkel-Huyninck, W., … Mayr, A. C. (1979). Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer treatment reports, 63(5), 827-834.
Salem, J. E., Nguyen, L. S., Moslehi, J. J., Ederhy, S., Lebrun-Vignes, B., Roden, D. M., Funck-Brentano, C., & Gougis, P. (2021). Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. European heart journal, 42(38), 3915-3928. https://doi.org/10.1093/eurheartj/ehab362
Lentz, R., Feinglass, J., Ma, S., & Akhter, N. (2019). Risk factors for the development of atrial fibrillation on ibrutinib treatment. Leukemia & lymphoma, 60(6), 1447-1453. https://doi.org/10.1080/10428194.2018.1533129
Singla, A., Hogan, W. J., Ansell, S. M., Buadi, F. K., Dingli, D., Dispenzieri, A., Gastineau, D. A., Gertz, M. A., Hayman, S. R., Inwards, D. J., Johnston, P. B., Lacy, M. Q., Litzow, M. R., Micallef, I. N., Porrata, L. F., & Kumar, S. K. (2013). Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biology of blood and marrow transplantation, 19(8), 1233-1237. https://doi.org/10.1016/j.bbmt.2013.05.019
Berezin, A. E. (2015). Biologicheskie markery v diagnostike, prognozirovanii i otsenke effektivnosti terapii serdechnoi nedostatochnosti s sokhranennoi i snizhennoi kontraktil'noi funktsiei [Biological markers in the diagnosis, prognosis and evaluation of the effectiveness of therapy for heart failure with preserved and reduced contractile function]. Sertseva nedostatnist, (2), 16-27. [in Russian].
Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T. M., Ky, B., Štěrba, M., Cardinale, D., Cohen-Solal, A., Tocchetti, C. G., Farmakis, D., Bergler-Klein, J., Anker, M. S., Von Haehling, S., Belenkov, Y., … Lyon, A. R. (2020). Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European journal of heart failure, 22(11), 1966-1983. https://doi.org/10.1002/ejhf.2017
Michel, L., Mincu, R. I., Mahabadi, A. A., Settelmeier, S., Al-Rashid, F., Rassaf, T., & Totzeck, M. (2020). Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. European journal of heart failure, 22(2), 350-361. https://doi.org/10.1002/ejhf.1631
Xue, K., Gu, J. J., Zhang, Q., Liu, X., Wang, J., Li, X. Q., Luo, J., Hernandez-Ilizaliturri, F. J., Fernandez, S. F., Czuczman, M. S., Cao, J., Hong, X., & Guo, Y. (2016). Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial. Oncotarget, 7(22), 32519-32531. https://doi.org/10.18632/oncotarget.8685
Mueller, C., McDonald, K., de Boer, R. A., Maisel, A., Cleland, J., Kozhuharov, N., Coats, A., Metra, M., Mebazaa, A., Ruschitzka, F., Lainscak, M., Filippatos, G., Seferovic, P. M., Meijers, W. C., Bayes-Genis, A., Mueller, T., Richards, M., Januzzi, J. L., Jr, & Heart Failure Association of the European Society of Cardiology (2019). Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European journal of heart failure, 21(6), 715-731. https://doi.org/10.1002/ejhf.1494
Pavo, N., Raderer, M., Hülsmann, M., Neuhold, S., Adlbrecht, C., Strunk, G., Goliasch, G., Gisslinger, H., Steger, G. G., Hejna, M., Köstler, W., Zöchbauer-Müller, S., Marosi, C., Kornek, G., Auerbach, L., Schneider, S., Parschalk, B., Scheithauer, W., Pirker, R., Drach, J., … Pacher, R. (2015). Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart (British Cardiac Society), 101(23), 1874-1880. https://doi.org/10.1136/heartjnl-2015-307848
López-Sendón, J., Álvarez-Ortega, C., Zamora Auñon, P., Buño Soto, A., Lyon, A. R., Farmakis, D., Cardinale, D., Canales Albendea, M., Feliu Batlle, J., Rodríguez Rodríguez, I., Rodríguez Fraga, O., Albaladejo, A., Mediavilla, G., González-Juanatey, J. R., Martínez Monzonis, A., Gómez Prieto, P., González-Costello, J., Serrano Antolín, J. M., Cadenas Chamorro, R., & López Fernández, T. (2020). Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. European heart journal, 41(18), 1720-1729. https://doi.org/10.1093/eurheartj/ehaa006
Beer, L. A., Kossenkov, A. V., Liu, Q., Luning Prak, E., Domchek, S., Speicher, D. W., & Ky, B. (2016). Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction. Circulation research, 119(10), 1135-1144. https://doi.org/10.1161/CIRCRESAHA.116.309004
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010). Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology, 55(3), 213-220. https://doi.org/10.1016/j.jacc.2009.03.095
Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Laverdière, C., Michon, B., Schorin, M. A., & Sallan, S. E. (2012). Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. Journal of clinical oncology, 30(10), 1042-1049. https://doi.org/10.1200/JCO.2010.30.3404
Loar, R. W., Noel, C. V., Tunuguntla, H., Colquitt, J. L., & Pignatelli, R. H. (2018). State of the art review: Chemotherapy-induced cardiotoxicity in children. Congenital heart disease, 13(1), 5-15. https://doi.org/10.1111/chd.12564
Vianello, E., Dozio, E., Tacchini, L., Frati, L., & Corsi Romanelli, M. M. (2019). ST2/IL-33 signaling in cardiac fibrosis. The international journal of biochemistry & cell biology, 116, 105619. https://doi.org/10.1016/j.biocel.2019.105619
Aula, H., Skyttä, T., Tuohinen, S., Luukkaala, T., Hämäläinen, M., Virtanen, V., Raatikainen, P., Moilanen, E., & Kellokumpu-Lehtinen, P. L. (2020). ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast (Edinburgh, Scotland), 49, 183-186. https://doi.org/10.1016/j.breast.2019.12.001
Frères, P., Bouznad, N., Servais, L., Josse, C., Wenric, S., Poncin, A., Thiry, J., Moonen, M., Oury, C., Lancellotti, P., Bours, V., & Jerusalem, G. (2018). Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC cancer, 18(1), 102. https://doi.org/10.1186/s12885-018-4015-4
Huang, G., Zhai, J., Huang, X., & Zheng, D. (2018). Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy. Medicine, 97(38), e12447. https://doi.org/10.1097/MD.0000000000012447
Samura, B., & Panasenko, M. (2022). SST2 AS a predictor of statin treatment efficacy in patients with multiple myeloma. Georgian medical news, (326), 18-22.
Del Pinto, R., & Ferri, C. (2018). Inflammation-Accelerated Senescence and the Cardiovascular System: Mechanisms and Perspectives. International journal of molecular sciences, 19(12), 3701. https://doi.org/10.3390/ijms19123701
FDA. (n.d.). 510(k) Substantial equivalence determination decision summary (No K093758). http://www.accessdata.fda.gov/cdrh_docs/reviews/K093758.pdf
Syvolap, V. D., & Lashkul, D. A. (2014). Vzaiemozviazky mizh rivnem markeriv fibrozu ST2, halektynu-3, strukturno-funktsionalnymy parametramy livoho shlunochka ta funktsiieiu nyrok pry khronichnii sertsevii nedostatnosti ishemichnoho henezu [The relationship between the level of markers of fibrosis ST2, galectin-3, structural, functional parameters of the left ventricle and renal function in patients with ischemic chronic heart failure]. Zaporozhye medical journal, (5), 13-17. [in Ukrainain].
Lok, D. J., Lok, S. I., Bruggink-André de la Porte, P. W., Badings, E., Lipsic, E., van Wijngaarden, J., de Boer, R. A., van Veldhuisen, D. J., & van der Meer, P. (2013). Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clinical research in cardiology, 102(2), 103-110. https://doi.org/10.1007/s00392-012-0500-y
Meijers, W. C., Januzzi, J. L., deFilippi, C., Adourian, A. S., Shah, S. J., van Veldhuisen, D. J., & de Boer, R. A. (2014). Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. American heart journal, 167(6), 853-60.e4. https://doi.org/10.1016/j.ahj.2014.02.011
van der Velde, A. R., Gullestad, L., Ueland, T., Aukrust, P., Guo, Y., Adourian, A., Muntendam, P., van Veldhuisen, D. J., & de Boer, R. A. (2013). Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circulation. Heart failure, 6(2), 219-226. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000129
Chen, A., Hou, W., Zhang, Y., Chen, Y., & He, B. (2015). Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. International journal of cardiology, 182, 168-170. https://doi.org/10.1016/j.ijcard.2014.12.137
Weir, R. A., Petrie, C. J., Murphy, C. A., Clements, S., Steedman, T., Miller, A. M., McInnes, I. B., Squire, I. B., Ng, L. L., Dargie, H. J., & McMurray, J. J. (2013). Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circulation. Heart failure, 6(3), 492-498. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000146
Thijssen, V. L., Heusschen, R., Caers, J., & Griffioen, A. W. (2015). Galectin expression in cancer diagnosis and prognosis: A systematic review. Biochimica et biophysica acta, 1855(2), 235-247. https://doi.org/10.1016/j.bbcan.2015.03.003
Felker, G. M., Fiuzat, M., Shaw, L. K., Clare, R., Whellan, D. J., Bettari, L., Shirolkar, S. C., Donahue, M., Kitzman, D. W., Zannad, F., Piña, I. L., & O'Connor, C. M. (2012). Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circulation. Heart failure, 5(1), 72-78. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963637
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
